Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD421 (Barhemsys) for PONV Prophylaxis
NCT01991821Phase 3Completed
- Sponsor
- Acacia Pharma Group Plc
- Start
- Jul 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of amisulpride in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Acacia Pharma Group Plc. Primary endpoint: Complete Response (no Emesis, Significant Nausea or Rescue Medication). Started Jul 2013; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT01991821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01991821.